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Abstract: Biased agonism is one of the fastest growing topics in G protein-coupled receptor pharmacology; moreover,  
biased agonists are used in the clinic today: carvedilol (Coreg
®) is a biased agonist of beta-adrenergic receptors.   
However, there is a general lack of understanding of biased agonism when compared to traditional pharmacological  
terminology. Therefore, this review is designed to provide a basic introduction to classical pharmacology as well as  
G protein-coupled receptor signal transduction in order to clearly explain biased agonism for the non-scientist clinician  
and pharmacist. Special emphasis is placed on biased agonists of the beta-adrenergic receptors, as these drugs are highly  
prescribed, and a hypothetical scenario based on current clinical practices and proposed mechanisms for treating disease  
is discussed in order to demonstrate the need for a more thorough understanding of biased agonism in clinical settings.  
Since biased agonism provides a novel mechanism for treating disease, greater emphasis is being placed to develop  
biased agonists; therefore, it is important for biased agonism to be understood in equal measure of traditional   
pharmacological concepts. This review, along with many others, can be used to teach the basic concepts of biased   
agonism, and this review also serves to introduce the subsequent reviews that examine, in more depth, the relevance of  
biased agonism towards the angiotensin type 1 receptor, parathyroid hormone receptor, and natural biased ligands towards  
chemokine receptors. 
Keywords:  Arrestin, beta-adrenergic receptors, biased agonism, G protein-coupled receptors (GPCRs), G protein-coupled   
receptor kinases (GRKs), pharmacology.  
INTORDUCTION 
  Biased agonism, also known as functional selectivity, is a 
rather recent discovery regarding the fundamental nature of 
how G protein-coupled receptors function. Put simply, bi-
ased agonism refers to a ligand’s ability to signal through a 
subset of the classical signaling pathways initiated by the 
cognate receptor. Importantly, at least one biased agonist is 
in widespread clinical use: carvedilol (Coreg CR
®) [1]. 
Therefore, it is important for clinicians, pharmacists, and 
educators to have a general understanding of biased agonism. 
The goal of this review is to: 1) describe biased agonism in 
the context of general pharmacological principles, 2) intro-
duce the biased agonists of beta-adrenergic receptors (-
ARs), 3) discuss possible clinical benefits and complications 
of these compounds, and 4) introduce the proceeding de-
tailed reviews about specific biased agonists.  
CLASSICAL PHARMACOLOGICAL DEFINITIONS 
OF LIGANDS AND LIGAND EFFECTS 
  The following is a list of terms that are commonly used 
in pharmacology, but when dealing with biased agonism of 
antagonists it is wise to revisit the original definition and 
how these definitions have “evolved” as we have become 
more aware of the complexities of receptor ligand interac-
tions and the subsequent biological effect of said interaction.  
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Ligand – a molecule that binds to a receptor. 
Potency – the measurement of the concentration of a 
ligand in respect to a biological response (Fig. 1). 
Potency is generally denoted by an EC50 value, 
which indicates the ligand concentration required to 
reach half maximal effect. 
Efficacy – the measurement of the maximal response 
of a ligand (Fig. 1). 100% efficacy is generally defined 
by the endogenous agonist, and represents the upper 
asymptote of a sigmoidal curve. 
Agonist – a molecule targeting a receptor that elicits 
a biological response; traditionally this response was 
similar to the endogenous ligand’s effects. However, 
an agonist can have either increased or decreased 
potency and/or efficacy. Generally, an agonist with 
markedly reduced efficacy is termed a partial agonist 
for it has partial effects. 
Antagonist – a molecule that blocks the action of the 
agonist and endogenous ligand. A classical example 
is the competitive antagonist which has no effect on 
the target receptor, yet binds to the receptor blocking 
an agonist from binding to the receptor and eliciting 
a biological effect. In Fig. (1), the addition of a 
competitive antagonist would shift the curve to the 
right; greater ligand concentration would be required 
to displace the antagonist and result in a biological 
effect. Biased Agonism Primer  Endocrine, Metabolic & Immune Disorders - Drug Targets, 2011, Vol. 11, No. 2    93 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Depiction of classical pharmacological terminology. De-
picted is a typical pharmacological dose-response curve using a 
linear Y-axis and a Log10 X-axis; the curve that is generated is a 
sigmoidal curve. The midpoint of the curve (50% response repre-
sented by ) is the effective concentration 50 (EC50), which is used 
to rank agonists. A compound can have greater or lesser efficacy 
and potency (shown as shaded arrows). 
  The above definitions have been challenged previously 
and thus new ideas have entered into the classical pharma-
cological lexicon; two instances deserve discussion: inverse 
agonism and selective receptor modulators. Inverse agonism, 
first described in 1982 [6], indicates that a ligand will pro-
duce negative efficacy. This phenomenon is attributed to 
receptors that display basal activity that is concentration-
dependently inhibited to an asymptote below the basal activ-
ity; ideally this would be towards no activity (an asymptote 
of 0). If this were to be depicted in Fig. (1), the sigmoidal 
curve would start at a positive integer (25 for example) and 
the inverse agonist would reduce the activity following a 
sigmoidal curve (from 25 to 0, for example). As with any 
agonist, the potency and efficacy could vary. Selective re-
ceptor modulators, first described in 1987 [7], are ligands 
that behave differently depending on the tissue being stud-
ied; they can be an agonist in one tissue and simultaneously 
an antagonist in another. Prototypical examples of selective 
receptor modulator are the selective estrogen receptor modu-
lators (SERMs). The mechanism underlying the paradoxical 
action of SERMs is the tissue specific expression of co-
activators and co-repressors of the estrogen receptors that are 
required for the ligand to act as an agonist or antagonist [8]. 
These early challenges to classical concepts of pharma- 
cological effects foreshadowed the growing complexities of 
ligand-receptor interactions and cellular signaling that are 
still being unmasked. Currently the definitions of the poten-
tial pharmacological action of a ligand are complex and can 
be defined observationally and functionally (Table 1). 
CLASSICAL GPCR SIGNALING AND REGULATION 
  Thus far, only G protein-coupled receptors (GPCRs) are 
reported to have biased agonists, and to understand biased 
agonism a basic understanding of GPCR-mediated signaling 
is required. Since GPCRs are the largest single grouping of 
receptors and represent the largest class of clinical drug tar-
gets [9], biased agonism and traditional agonists and antago-
nists will play a role in the treatment of a variety of diseases. 
Table 1.  Definitions of Ligands with Pharmacological Properties 
Class Type Operational Definition Molecular Mechanism(s)
Full
Ligand generates maximum receptor-mediated 
responses of all responses linked to the receptor.
Ligand binds to the receptor and induces a receptor conformation that results in 
maximum signaling of all signaling pathways linked to the receptor.
Partial
Ligand generates sub-maximum receptor-mediated 
responses of all responses linked to the receptor. 
Ligand binds to the receptor and induces a receptor conformation that results in sub-
maximum signaling of all signaling pathways linked to the receptor.
Inverse
Ligand generates receptor-mediated opposite  
(or negative) responses compared to the full agonist.
Ligand binds to the receptor and induces a receptor conformation that results in no 
signaling by all signaling pathways linked to the receptor.
Agonist
Functionally 
Selective
Ligand generates receptor-mediated responses of a 
subset of responses linked to the receptor.  A func-
tionally selective agonist can be either full or partial.
Ligand binds to the receptor and induces a receptor conformation that unequally 
activates the signaling pathways linked to the receptor.
Selective Receptor Modulation
Ligand behaves as an agonist in some cells and as an 
antagonist in other cells.
Differentially expressed co-factors interact with the receptor and modulate the type 
of conformational change induced by the agonist   
Competitive 
aka 
Surmountable
Ligand decreases the potency, but not efficacy, of an 
agonist (i.e., the full effect of the agonist can be 
restored at increased concentrations).
Several mechanisms can produce surmountable antagonism.  Commonly, the under-
lying mechanism is competition between reversible antagonist and agonist binding 
at the receptor binding pocket and thus blocking the binding of the agonist.   The 
phenomenon of surmountable antagonism, however, can also be produced by sev-
eral types of allosteric (a site on a receptor that is different from the agonist binding 
site) mechanisms. Antagonist
Non-competitive 
aka 
Insurmountable
Ligand decreases the efficacy of an agonist, but may 
or may not reduce potency of an agonist (i.e., the 
full effect of the agonist cannot be restored at  
increased concentrations).
Several mechanisms can produce insurmountable antagonism.  Common mecha-
nisms include: 1) irreversible binding of the antagonist ligand to the binding pocket; 
2) some types of allosteric mechanisms; and 3) interference of the antagonist with 
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  GPCRs are proteins that cross the plasma membrane 
seven times; their amino terminus is outside of the cell and 
the carboxy terminus within the cytoplasm. A GPCR is cou-
pled to an inactive GDP-bound G subunit and a G dimer 
(Fig.  2A). There are multiple G, G, and G subunits, 
which will not be discussed in detail in this review. Tradi-
tionally, an agonist binds to the receptor which initiates 
guanylyl exchange on the G subunit (GDP is exchanged for 
GTP), which places G into an active state. The active G 
and G then leave the receptor and bind to their respective 
targets in the cell, thus propagating the signal and initiating 
the cellular signaling cascade from the GPCR (Fig. 2B). This 
initiation is the beginning of cellular signaling and is typified 
by, but not limited to, activation (Gs) or inhibition (Gi) of 
adenyl cyclase production of cAMP, activation of phosphol-
ipase C (Gq/11) and RhoA (G12/13). 
  Shortly after activation of the GPCR, the GPCR is phos-
phorylated by a number of kinases (Fig. 2C). These phos-
phorylation events can be classified into two different varie-
ties: signaling-mediated and signaling-independent GPCR 
phosphorylation. Signaling-mediated GPCR phosphorylation 
is mediated by kinases that are directly activated by the 
GPCR signaling cascade such as PKA [10], which is   
activated by increased levels of cAMP, and PKC [11], which 
is activated by multiple signaling pathways but is classically 
downstream of phospholipase C. Importantly, these kinases, 
once activated by a GPCR, can phosphorylate other GPCRs; 
a process called heterologous desensitization [12]. Signaling-
independent GPCR phosphorylation occurs through GPCR 
kinases (GRKs), which have been shown to phosphorylate 
GPCRs that are in an active state, such as when a GPCR is 
bound to an agonist [13, 14]. Phosphorylation of GPCRs 
initiates the desensitization process [15] through recruitment 
of -arrestins [16]. -arrestins are scaffolding proteins that 
bind to the phosphorylated receptor [17] and are involved in 
clathrin-mediated GPCR internalization [18]. 
  In summary, basic GPCR action relies on an agonist to 
activate the G and G subunits to initiate signaling and 
then the GPCR is phosphorylated/desensitized and internal-
ized. At least that was the view of GPCR-mediated signaling 
for many years until it was realized that -arrestins are sig-
naling molecules in their own right [19]. Therefore, the de-
sensitization process initiated by phosphorylation activates 
unique cellular signaling pathways. Consequently GRKs, 
which can phosphorylate a GPCR in a signaling-independent 
fashion, are involved in signal propagation. This raises an 
interesting question: can the GRK/arrestin pathway be acti-
vated independently of classical GPCR-mediated (G and 
G) signaling? Indeed it can, as this is one form of biased 
agonism. 
BIASED AGONISM 
   Biased agonism refers to the ability of a ligand to acti-
vate a subset of a receptor’s signaling cascade. For GPCRs 
this subset is either the -arrestin-mediated signaling events 
or G and G events but not both pathways simultaneously 
as would occur with a traditional agonist. Consequently, bi-
ased agonists that only activate the -arrestin pathway appear 
to be antagonists if the only output that is examined is the 
G- and G-mediated events, which is the traditional 
method for classifying ligands. Consequently, the -AR bi-
ased agonist carvedilol has been marketed as a -AR antago-
nist because its -arrestin activating pathway was not dis-
covered until 2007 [1]. On the other hand, biased agonists 
that activate G and G have been classified as agonists, 
which is closer to their true identity than the previous exam-
ple. Yet these agonists would be long acting for they would 
not recruit -arrestins and thus escape the signaling-
independent desensitization and internalization process. 
  GPCR-mediated signaling is dependent on the conforma-
tion (3-Dimensional sape) of the receptor [20]. Agonists shift 
the inactive (neutral) receptor conformation towards one that 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Depiction of classical GPCR initiated signaling and desen-
sitization. All cartoons were created from published crystal struc-
tures. (A) Basal state of a GPCR docked to the heterotrimeric G-
protein. (B) Canonical ligand initiated signaling separates and the 
G and G subunits from each other and the receptor allowing for 
each to initiate signal transduction cascades. (C) Homologous de-
sensitization is initiated by GRK-dependent phosphorylation of the 
receptor and signaling-induced phosphorylation of the receptor by 
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promotes signaling. Pure competitive receptor antagonists do 
not alter the conformation of the receptor yet prevent the 
binding of an agonist and therefore prevent agonists from 
shifting receptors to the active conformation. Inverse an-
tagonists not only prevent the binding of agonists, but they 
also promote a shift of constitutively active receptors to the 
inactive conformation. Since the specificity of GRKs are 
believed mainly to be determined by the conformation of the 
GPCR [21, 22] and -arrestins bind to phosphorylated recep-
tors [16], this would indicate that most -arrestin biased ago-
nists place the receptor into a confirmation that is recognized 
by the GRK but not the G heterotrimer allowing for 
phosphorylation and -arrestin recruitment sans classical 
GPCR-mediated signaling. There is the possibility that a 
GPCR can interact directly with a -arrestin independent of 
phosphorylation [23]; however, these studies were conducted 
solely via cellular assays with mutant receptors that cannot 
be phosphorylated, which indicates that this pathway is pos-
sible but may not occur in natural conditions. Supporting 
this, transgenic mice expressing a 1-AR that cannot be 
phosphorylated by GRKs develop more severe cardiac dys-
function after prolonged isoproterenol (a -AR agonist) 
stimulation than mice expressing similar levels of wild-type 
1-ARs [24]. Taken together, the biochemical properties of 
biased agonists can be thought of as a partial conformational 
change, or more accurately a limited regional shift in the 
shape of the GPCR [25]. All proteins are three dimensional 
structures; thus it is not hard to imagine that there could be a 
shift in one area of the structure while there is little to no 
change in a second area. Using this concept, a GPCR will 
have a number of possible shapes; as depicted in the Venn 
diagram of Fig. (3), some shapes will initiate G and G as 
well as GRK/-arrestin signaling cascades (traditional ago-
nists) while other shapes only initiate G and G or 
GRK/-arrestin signaling cascades (biased agonists) or con-
fer no signal transduction (pure competitive antagonists and 
inverse agonists). 
  The biochemical basis of this shape change is actively 
being examined; however, some mechanisms can be deduced 
from the current literature. G proteins interact with the re-
ceptor in a small pocket near the membrane, and GRKs in-
teract with the same pocket, which is enlarged when an ago-
nist is bound to the receptor [22]. Therefore, the G-G 
heterotrimer and GRK cannot simultaneously interact with 
the GPCR due to steric hindrance. Thus, biased agonists 
must either activate undocked receptors (GPCRs that are not 
bound to G proteins) or the conformation induced by the 
biased agonist passively displaces the G-G heterotrimer 
from the GPCR. In this instance “passively” indicates that 
the GPCR is not initiating guanylyl exchange on the G 
subunit, but is initiating a separation of the heterotrimer from 
the GPCR. Upon docking of the GRK to the GPCR, the re-
ceptor will be phosphorylated and -arrestins will be re-
cruited thus allowing for -arrestin-mediated signaling. 
CARVEDILOL AND ALPRENOLOL 
  Carvedilol and alprenolol are now rather old -adrenergic 
receptor antagonists, aka -blockers, that have recently been 
shown to actually behave as biased agonists [1, 26]. Alpre-
nolol was first published in a clinical study in 1968 [27] and 
is no longer actively marketed; whereas carvedilol is a third 
generation -blocker, approved by the FDA in 1995, that has 
relatively recently (9/5/2007) been classified as a generic 
drug [28, 29]. Additionally, on 20 October 2006 the FDA 
approved a controlled release tablet of carvedilol from 
GlaxoSmithKline marketed as Coreg CR
® for the treatment 
of heart failure, hypertension, and post-myocardial infarction 
left ventricular dysfunction [29]. The total combined sales in 
2009 of carvedilol (Coreg CR
® and generic carvedilol) are 
over 0.5 billion dollars, which represents over 17 million 
prescriptions [30]. Therefore, there are many people being 
treated with a biased agonist, and since carvedilol is a well 
tolerated -blocker [31] it will likely be among the first line 
choices for many physicians prescribing generic -blockers. 
Furthermore, there are additional -blockers that have   
not been tested for biased agonism, and there are likely to  
be -blockers that are formulated in the future, thus there 
may be more clinically viable -blockers that are also biased 
agonists than just carvedilol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Modified Venn diagram representing the relationship be-
tween GPCR shape and signaling. Receptor shape dictates signal-
ing, and there is only a certain range of shapes that can be formed 
by a functional GPCR (thick black box). Within those range of 
shapes some will resulted in no signaling (clear box), some in tradi-
tional signaling (cross hatched box), while others in biased agonism 
of the G-protein (rightward slant) or -arrestins (leftward slant). 
  As a biased agonist carvedilol and alprenolol bind to -
ARs and prevent the endogenous agonists, norepinephrine 
and epinephrine, from binding to the receptor and initiating 
full receptor-mediated signal transduction. Since the -ARs 
predominately active Gs-mediated production of cAMP, 
monitoring production of cAMP or GTP-bound Gs was 
used, along with binding studies, to show that carvedilol and 
alprenolol are -blockers. In retrospect, these experiments 
were not sufficient to fully characterize carvedilol and alpre-
nolol as the GRK/-arrestin pathway was ignored. The full 
extent of -AR initiated GRK/-arrestin signaling is actively 
being explored; however, it is clear that both carvedilol and 
alprenolol lead to activation of the epidermal growth factor 
receptor (EGFR) through -arrestins [26].  96    Endocrine, Metabolic & Immune Disorders - Drug Targets, 2011, Vol. 11, No. 2  Bradley T. Andresen 
  The EGFR is infamous for its role in cancer [32-34]; 
however, it is also involved in regulation of nitric oxide 
(NO) production [35, 36], and has been shown to induce 
relaxation of various vascular beds [37, 38]. Consequently, it 
is not surprising that carvedilol has been shown to induce 
NO production [39] and that a significant portion of its   
antihypertensive properties are dependent on NO produc- 
tion [40]. Moreover, NO and drugs that enhance NO effects 
are used as a treatment for a variety of cardiovascular   
diseases [41]; therefore, it is likely that many of the benefi-
cial properties that make carvedilol unique compared to 
other  -blockers are due to carvedilol’s biased agonism 
properties. 
POTENTIAL RISKS OF PRESCRIBING A -AR  
BIASED AGONIST 
  Foremost, there is no evidence that -AR biased agonists 
cause cancer. Thus far antihypertensive drugs, as a class, 
have been shown to have little to no effect on a patient’s risk 
of developing cancer [42-44]; however, no clinical or basic 
studies have been conducted specifically with carvedilol. 
Anecdotally, biased agonists have been prescribed for more 
than 15 years and there is no report that a biased agonist -
blocker is linked to cancer. Additionally, stimulation of the 
EGFR by a GRK/-arrestin pathway is not identical to acti-
vating EGFR directly [45, 46], and there is a report indicat-
ing that carvedilol inhibits multiple cancer cell lines growth 
in vitro [47]. Therefore, activation of the EGFR by carvedilol 
is a greater good due to the role of NO in the cardiovascular 
system than the hypothetical risk of inducing a cancer. But, 
there is a select group of patients that pose an interesting 
scenario for why understanding and classifying antagonists 
as biased agonists versus traditional antagonists is important 
for physicians and pharmacists. 
  Within the past decade multiple cellular and animal mod-
els have demonstrated that -ARs are involved in multiple 
types of tumor proliferation [48, 49], invasion [50-53], and 
in vivo metastasis [54, 55]; moreover -ARs are present on 
many human tumors [53, 55]. In all cases where -blockers 
(generally propranolol) were used, it was found that blocking 
-ARs reduces tumor proliferation, invasiveness, and metas-
tasis suggesting that -blockers can be used as antineoplastic 
drugs. This is supported by two lines of clinical evidence. 
First -blockers reduce the risk of a patient developing cancer 
[44, 56]. Second, propranolol (a -blocker) is considered   
a first line of therapy for infantile hemangiomas, which is 
benign tumor-like malformation, due to propranolol-induced 
rapid involution of the hemangioma [57]. Therefore it is   
reasonable to prescribe a -blocker to cancer patients;   
however, as the EGFR is involved in many cancers [32-34] 
care should be used when prescribing a drug that activates 
the EGFR, such as biased agonists. 
  To demonstrate this concern a closer look at -ARs in 
breast cancer serves as an interesting example. Most breast 
cancers express -ARs [55, 58], and there is a striking   
correlation between EGFR levels and 2-AR levels [58]. 
Furthermore, in a breast cancer cell line (MCF-7) that is   
routinely used as a cellular model of breast cancer, -ARs 
stimulate the production of EGFRs, and EGF leads to   
the synthesis of the catecholamine biogenesis pathway and 
increased levels of epinephrine [58]. Therefore, a vicious 
circle is formed where the EGFRs, which are a target of the 
anti-neoplastic agent Herceptin®, are producing agonists to 
the -ARs, which are involved in breast cancer metastasis 
[54]. Completing the circle, -AR activation leads to the 
expression of more EGFRs, which could conceivably lead  
to acquired resistance to EGFR inhibitors resulting in the 
need to prescribe higher doses of the drug. Thus, treating 
breast cancer patients with an EGFR inhibitor and -blocker 
is recommended because the -blocker can reduce tumor 
proliferation and metastasis [49, 54]; thus, increasing the 
probability of a optimistic prognosis. Yet, treatment with a 
biased agonist would activate the EGFR, which may be 
counterproductive.  
  Thus far no in vivo tests or human trials have been con-
ducted to examine the role of carvedilol in breast cancer, and 
as stated previously carvedilol may be a viable anti-
neoplastic agent specifically for breast cancer [47]. However, 
since EGFR expression is associated with decreased survival 
of breast cancer patients [59], activating the EGFR through a 
biased agonist may not be beneficial even if the patient is 
taking an EGFR inhibitor. This is due to there being a greater 
likelihood that the EGFR would be activated as the concen-
tration of the inhibitor decreases (normal clearance and bio-
distribution) or if the patient fails to take their medication as 
prescribed. Consequently, the EGFR might be activated by 
the biased agonist. Additionally, if transactivation of the 
EGFR signals similarly to EGF-mediated activation of the 
receptor in breast tumors, biased agonists would produce 
epinephrine [58]. This would reduce the clinical efficacy of 
the -blocker/biased agonist due to an increased local con-
centration of epinephrine and competition for binding sites, 
suggesting that the patient would acquire resistance to -AR 
biased agonists. This resistance would indicate that the -
ARs are likely being activated, and if a biased agonists is 
used at a higher dosage this scenario could become repeti-
tive. More studies should be conducted to determine the   
potential positive or negative roles of -AR biased agonists, 
such as carvedilol, in breast cancer treatment. Until these 
studies are conducted, biased agonists that activate growth 
promoting pathways should be used with care in any patient 
that is currently diagnosed with any cancer. As stated previ-
ously, there is no evidence that these drugs cause cancer,   
but there is also no in vivo or clinical evidence to counter  
the hypothesis that they may promote an existing cancer. 
Therefore, in these cases a pure -blocker may be more   
appropriate. 
  As biased agonism is a new concept, there are many cli-
nicians, pharmacists, and educators that do not know the 
possible ramifications of these drugs. Therefore, it is impor-
tant to identify biased agonists. Importantly, biased agonism 
is a great new concept that provides a revolution in drug de-
velopment and treatment of a variety of diseases. Carvedilol 
demonstrates that biased agonism is clinically viable, safe, 
and can provide additional beneficial clinical characteristics 
compared to traditional antagonists. Biased Agonism Primer  Endocrine, Metabolic & Immune Disorders - Drug Targets, 2011, Vol. 11, No. 2    97 
CONCLUSION 
  The preceding section demonstrates that there is a need 
for the medical community to understand and continue to 
study biased agonism; additionally, biased agonism is an 
important new concept in pharmacology that has clinical 
relevance today.  Coreg CR
® and the generic carvedilol are 
currently prescribed to millions of people, and there are 
situations where a non-biased agonist -blocker may be a 
preferred treatment.  Biased agonists are most easily de-
scribed as an agonist that activates only one portion of a re-
ceptor’s signaling pathway while inhibiting the other portion.  
Therefore, all GRK/-arrestin biased agonists will appear to 
be antagonists when only examining G protein-mediated 
signaling, as is the case of most drug discovery programs.  
Due to the current clinical use of biased agonists, it is impor-
tant for physicians and pharmacists to understand which 
drugs are biased agonists and in which cases they should be 
used and avoided.  Educators too should begin teaching bi-
ased agonism alongside traditional pharmacological defini-
tions thus allowing for at least one more definition to be 
added to the initial list. 
Biased Agonist – a molecule that activates: 1) the 
GRK/-arrestin signaling pathways of a GPCR   
independent of the G trimer, or 2) the G 
trimer signaling pathways of a GPCR independent of 
GRK/-arrestin.
 
ABBREVIATIONS 
cAMP  =  3'-5'-cyclic adenosine monophosphate 
EC50 =  Effective  concentration  50% 
FDA  =  United States Food and Drug Administration 
GDP =  Guanosine-5'-diphosphate 
GTP =  Guanosine-5'-triphosphate 
PKA  =  Protein kinase A 
PKC  =  Protein kinase C 
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